Skip to main content
Equibles
PCRX logo

PCRX · Pacira BioSciences, Inc.

Track PCRX — free

Use PCRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$26.35 -0.25 (-0.94%) At close · Sep 4
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.05B
Shares
39.86M

PCRX metrics

83 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$26.35
Market cap
$1.05B

Price action

19 metrics
Price change (1W)
+2.3%
Price change (30D)
+7.9%
Price change (3M)
+15.8%
Price change (6M)
+19.8%
Price change (YTD)
+1.8%
Price change (1Y)
-1.4%
Trailing year
Price change (5Y)
-53.7%
52-week high
$27.62
52-week low
$19.16
Change from 52-week high
-4.6%
Change from 52-week low
+37.5%
Annualized volatility
36.9%
Beta
0.3
RSI (14D)
59.5
Price vs SMA 50
+3.6%
Price vs SMA 200
+10.6%
Avg volume (3M)
560,155
Relative volume
0.9
Average dollar volume
$14.01M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
39.86M

Valuation

12 metrics
P / E (TTM)
73.2
Trailing earnings · reciprocal yield 1.4%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.4×
reciprocal yield 71.0%
P / book
1.6
reciprocal yield 64.0%
FCF yield
17.1%
TTM · current market cap
Buyback yield
14.1%
P / FCF
5.9
reciprocal yield 17.1%
P / operating cash flow
5.6
reciprocal yield 17.9%
Earnings yield
1.4%

Historical valuation

8 metrics
P / E historical average (3Y)
42.0×
reciprocal yield 2.4%
P / E historical average (5Y)
42.0×
reciprocal yield 2.4%
EV / revenue historical average (3Y)
1.8×
reciprocal yield 56.5%
EV / revenue historical average (5Y)
1.8×
reciprocal yield 56.5%
EV / EBIT historical average (3Y)
33.5×
reciprocal yield 3.0%
EV / EBIT historical average (5Y)
33.5×
reciprocal yield 3.0%
EV / EBITDA historical average (3Y)
23.3×
reciprocal yield 4.3%
EV / EBITDA historical average (5Y)
23.3×
reciprocal yield 4.3%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
14.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
79.2%
Operating margin
2.7%
Trailing 12 months
Net margin
2.0%
Gross profit (TTM)
—
Operating profit (TTM)
$19.87M
Net income (TTM)
$14.64M
Trailing 12 months
Diluted EPS (TTM)
$0.36
FCF margin
24.1%
Effective tax rate
17.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-84.29

Growth

11 metrics
Revenue growth YoY
+6.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$746.16M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-11.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+2.9%
Revenue CAGR (5Y)
+11.1%
EPS CAGR (3Y)
-22.2%
EPS CAGR (5Y)
-45.5%
FCF CAGR (3Y)
+5.9%
FCF CAGR (5Y)
+28.4%

Quality

14 metrics
Return on equity
2.2%
Return on assets
1.2%
Debt / equity
—
Current ratio
5.0
EBITDA (TTM)
$105.03M
Free cash flow (TTM)
$179.51M
Quick ratio
3.9
Interest coverage
1.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$205.88M
Total assets
$1.24B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$187.66M
Capital expenditures (TTM)
$8.15M
R&D (TTM)
$122.08M
SG&A (TTM)
$379.16M
Stock compensation (TTM)
$55.97M
R&D / revenue
16.4%
Stock compensation / revenue
7.5%

Ownership (13F)

3 metrics
13F filers
255
13F filer change QoQ
+13
Institutional ownership
109.9%

Short interest

3 metrics
Short interest
18.3%
Latest settlement · 8.1 days to cover
Days to cover
8.1d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$214,322
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1396814 CUSIP 695127100 13F (30d) 161 filings 160 filers Visit website Investor relations